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The Journal of Immunology
IL-12+IL-18 Cosignaling in Human Macrophages and Lung
Epithelial Cells Activates Cathelicidin and Autophagy,
Inhibiting Intracellular Mycobacterial Growth
Rui Yang,*,†,1 Enzhuo Yang,‡,1 Ling Shen,‡ Robert L. Modlin,x,{ Hongbo Shen,* and
Zheng W. Chen‡,‖
The ability of Mycobacterium tuberculosis to block host antimicrobial responses in infected cells provides a key mechanism for
disease pathogenesis. The immune system has evolved to overcome this blockade to restrict the infection, but it is not clear
whether two key innate cytokines (IL-12/IL-18) involved in host defense can enhance antimycobacterial mechanisms. In this study,
we demonstrated that the combination of IL-12 and IL-18 triggered an antimicrobial response against mycobacteria in infected
macrophages (THP-1 and human primary monocyte-derived macrophages) and pulmonary epithelial A549 cells. The inhibition of
intracellular bacterial growth required p38–MAPK and STAT4 pathways, the vitamin D receptor, the vitamin D receptor–derived
antimicrobial peptide cathelicidin, and autophagy, but not caspase-mediated apoptosis. Finally, the ability of IL-12+IL-18 to
activate an innate antimicrobial response in human primary macrophages was dependent on the autonomous production of
IFN-g and the CAMP/autophagy pathway. Together, these data suggest that IL-12+IL-18 cosignaling can trigger the antimicrobial
protein cathelicidin and autophagy, resulting in inhibition of intracellular mycobacteria in macrophages and lung epithelial
cells. The Journal of Immunology, 2018, 200: 2405–2417.
A
s part of the first line of defense against Mycobacterium
tuberculosis, the innate immune response involves
macrophages and lung epithelial cells (1, 2). Within
macrophages, M. tuberculosis can counteract the host defense via
multiple strategies, resulting in its survival. In addition, M. tu-
berculosis infects pulmonary epithelial cells, resulting in the
production of proinflammatory cytokines (e.g., TNF-a), chemo-
kines (CXCL8, CXCL10, CCL5, and CCL2), NO, and antimi-
crobial peptides (b-defensin-2, cathelicidin), but the bacteria are
not eliminated (3–5). Despite the development of an adaptive
T cell response, the infection can progress. M. tuberculosis is
estimated to have infected one third of the world’s population and,
as a result of its ability to evade the human immune response, kills
.4000 people each day (6).
A better understanding of the host–M. tuberculosis interaction is
required to develop improved intervention strategies to block
transmission of M. tuberculosis and reactivation of disease in the
already-infected population. A successful immune response
against M. tuberculosis involves the distinct and overlapping
contributions of the innate and adaptive immune systems, in-
cluding the production of cytokines by the innate immune re-
sponse, which instructs the adaptive T cell response (7, 8). For
example, two key cytokines produced upon activation of the in-
nate immune response by mycobacterial infection are IL-12 and
IL-18 (9–16), which synergize to directly activate the adaptive
T cell response toward Th1 cell differentiation (17). There is ev-
idence that the combination of IL-12 and IL-18 can directly ac-
tivate the innate immune system by inducing IFN-g production in
NK cells (18) and macrophages (19–21). Yet it is not known
whether IL-12 plus IL-18 (IL-12+IL-18) directly triggers an an-
timicrobial response against M. tuberculosis in infected cells. To
address this gap, we investigated whether IL-12 and IL-18 coop-
erate to directly activate a microbicidal pathway against intra-
cellular mycobacteria in infected monocytes/macrophages, as well
as pulmonary epithelial cells.
Our initial studies indicated that IL-12 or IL-18 alone had no
effect on the viability of intracellular mycobacteria and that only
cotreatment of infected macrophages with IL-12+IL-18 inhibited
bacterial growth. Concomitantly, mRNAs encoding for the anti-
microbial peptides CAMP and DEFB4A, as well as protein levels
of CAMP, were induced by IL-12+IL-18 treatment. The inhibition
of intracellular mycobacteria growth in A549 and THP-1 cells
mediated by IL-12+IL-18 was blocked by lentiviral transduction
vectors knocking down the expression of the vitamin D receptor
(VDR). Moreover, inhibition of the p38–MAPK or STAT4 sig-
naling pathway, as well as autophagy, in bacillus Calmette–Gue´rin
(BCG)-infected IL-12+IL-18–treated cells abrogated the IL-12
+IL-18 inhibition of intracellular mycobacteria growth. Furthermore,
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IL-12+IL-8 treatment induces IFN-g–dependent killing of intra-
cellular mycobacteria in human primary macrophages. These data
support the view that IL-12 and IL-18 cooperate to trigger an
innate immune response that, via the autonomous production of
IFN-g, inhibits the growth of intracellular mycobacteria in human
macrophages.
Materials and Methods
Ethics statement
The protocols for use of human blood samples for in vitro experimental
procedures were evaluated and approved by the institutional review boards
for human donors’ research and institutional biosafety committees at
Institut Pasteur of Shanghai and the University of Illinois–Chicago College
of Medicine. All studies were consistent with guidelines of Office for
Human Research Protections. All subjects were anonymized adults and
provided written informed consent.
Cells and reagents
The humanmonocyte cell line, THP-1, and the human lung adenocarcinoma
epithelial cell line, A549, were grown in RPMI 1640 supplemented with
L-glutamine (2 mM), sodium pyruvate (1 mM), and 10% heat-inactivated
FBS (all from Life Technologies). Prior to infection, THP-1 cells were
treated with 50 ng/ml PMA (Sigma-Aldrich) for 48 h to differentiate into
macrophages and then were washed three times with prewarmed PBS and
maintained in antibiotic-free media at 37˚C for further use. 293T cells
(purchased from Cell Bank, Shanghai, China), used to produce lentivirus
particles, were maintained in medium consisting of DMEM supplemented
with high glucose (4.5 g/l), L-glutamine (2 mM), sodium pyruvate (1 mM),
and 10% heat-inactivated FBS (all from Life Technologies) All cell lines in
use were routinely tested for Mycoplasma infection using a 16s-based
PCR, and new cultures were established monthly from frozen stocks.
Human PBMCs were isolated by density gradient centrifugation, using
Ficoll-Paque PLUS medium (GE), from buffy coats prepared from the
peripheral blood of healthy uninfected donors (Blood Center of Shanghai,
Shanghai Hospital). Adherent monocytes were enriched from PBMCs by
adherence on plastic culture plates for 2 h. Nonadherent cells were removed
via vigorous washing three times using prewarmed PBS. Humanmonocyte–
derived macrophages (hMDMs) were differentiated from adherent mono-
cytes in RPMI 1640 medium, supplemented with L-glutamine (2 mM),
sodium pyruvate (1 mM), 10% heat-inactivated FBS, and 50 ng/ml human
M-CSF (Novoprotein), for 7 d.
Human IL-12 was purchased from Miltenyi Biotec (order number 130-
096-704), and human IL-18 was purchased from BioVision (catalog number
4179-25); both cytokines were used at 50 ng/ml for stimulation. Human
TNF-a was purchased from Invitrogen (50 ng/ml; catalog number
10602HNAE25), and human IFN-b was purchased from PeproTech
(100 U/ml; catalog number 300-02BC). Neutralizing anti-human IL-18
mAb (clone 125-2H) and its isotype control (clone 11711), anti-human
IL-12 (catalog number AF-219-NA) and its isotype control (catalog
number AB-108), anti-human TNF-a (clone 28401) and its isotype control
(clone MAB002), and anti-human IFN-g (clone 25718) and its isotype
control (clone MAB003) were purchased from R&D Systems. MAPK
inhibitors (p38, SB203580, MEK1/2, and U0126-EtOH), NF-kB inhibitor
(PDTC), autophagy inhibitors (3-MA and wortmannin), and apoptosis
inhibitor (zVAD.fmk) (all from Beyotime) were used at 10 mM.
Bacteria culture, infection of cells, and measurement of
intracellular mycobacterial growth
Mycobacterium bovis BCG, Mycobacterium smegmatis, and M. tubercu-
losis H37Rv were grown in Difco Middlebrook 7H9 Broth with 10% oleic
acid–albumin–dextrose–catalase enrichment (Becton Dickinson), 0.05%
(v/v) Tween 80, and 0.2% (v/v) glycerol, at 37˚C, as reported (22). Cells
were infected with BCG at a multiplicity of infection (MOI) of 10 bacilli to
1 cell overnight. A549 cells were infected withM. smegmatis at an MOI of
1 bacillus to 1 cell for 4 h. hMDMs were infected with H37Rv at an MOI
of 4 for 4 h. Postinfection, extracellular noninternalized bacilli were re-
moved by washing with prewarmed PBS four times. Then, 5 3 104
mycobacteria-infected THP-1 cells, A549 cells, or hMDMs were cultured
in multiple wells with 50 ng/ml of each cytokine or combinations in the
presence or absence of 5 mg/ml neutralization Abs and their isotype
controls, or inhibitors (inhibitors were incubated with cells for 60 min and
then cytokines were added) in 200 ml of media without antibiotics in
96-well plates for 3 d. Then, wells were aspirated, and the infected cells
were lysed in 200 ml of sterile PBS with 0.067% SDS. A 10-fold serial
dilution was performed for quantitative culturing. Aliquots (100 ml) were
plated in triplicate on Middlebrook 7H10 agar plates supplemented with
10% oleic acid–albumin–dextrose–catalase for 2–3 wk until colonies were
large enough to be counted. Mycobacteria viability was quantified by
counting CFU. The percentage survival index, represented as intracellular
bacteria survival, was calculated as follows: survival index = 100 3 CFU
of treatment/CFU of media.
Quantification of gene expression
Total RNA was isolated from cells using a Direct-zol RNA Miniprep kit
(Zymo) based on the spin columns method. Contaminating genomic DNA
was removed using DNase I in columns, according to the manufacturer’s
protocols (Zymo). Then, RNA was reverse transcribed into cDNA using
mixed oligod-dT18 and random hexamers primers with HiScript II Q RT
SuperMix for qPCR (Vazyme). Real-time quantitative PCR (RT-qPCR)
reactions were performed in triplicate in 384-well plates on an Applied
Biosystems PRISM 7900HT Fast Real-Time PCR System using THUN-
DERBIRD qPCR Mix (Toyobo). Expression values were normalized to
those of the housekeeping gene EF1A. Oligonucleotides used for ampli-
fication are listed in Table I and were synthesized by Sangon Biotech.
Generation of lentiviral–short hairpin RNA and pCDH-GFP-
LC3 constructs, lentivirus preparation, and infection
The short hairpin RNA (shRNA) lentiviral construct (synthesized by Sangon
Biotech) targeting VDR (59-CTCCTGCCTACTCACGATAAA-39), STAT4
(59-GCGAGACTACAAAGTTATTAT-39), CAMP (59-GCTTCGTGCTA-
TAGATGGCAT-39), or control was cloned into pLKO.1 lentiviral vectors
using restriction enzymes AgeI and EcoRI (NEB). GFP-LC3 was cloned
from pEGFP-LC3 (human, plasmid number 24920; Addgene) and then
introduced into pCDH-Puro backbone to create the pCDH–GFP–LC3
construct. 293T cells were transfected with the lentivirus constructs,
pMD2G and pxPAS2 vectors, using HG-Trans293 transfection reagent
(Yeasen), according to the manufacturer’s protocol. After 24 h, media were
discarded, and fresh media were added. At days 4 and 5, the cell sus-
pension was collected, pooled, and filtered through a 0.45-mm filtration
unit (Merck/Millipore). Then, the virus particles were concentrated using a
GML-PC lentivirus concentration kit (Genomeditech), according to the
manufacturer’s protocol. A549 cells were treated with filtered viral su-
pernatant and 8 mg/ml Polybrene (Yeasen). Then, virus was aspirated, and
fresh media were added. THP-1 cells were infected by a spin-transduction
through 800 3 g for 2 h at 32˚C. Selection with puromycin (Yeasen) was
started at 48 h after viral transduction, and the selection concentrations for
A549 and THP-1 cells were 2 and 0.5 mg/ml, respectively.
Autophagy analysis
PMA-differentiated GFP-LC3–THP-1 cells were infected with BCG at an
MOI of 10:1 overnight. Cells were then treated with media or IL-12+IL-18
for 12 h. For the quantitation of autophagy, the percentages of GFP-LC3+
autophagic vacuoles in GFP-LC3–THP-1 cells were evaluated using
fluorescence microscopy, as described (23).
Western blotting
Cells were lysed by incubation in RIPA lysis buffer, supplemented with
1 mMPMSF (Yeasen), on ice for 5 min. Then, cell lysates were separated by
SDS-PAGE and transferred to a polyvinylidene difluoride membrane
(Merck/Millipore). After blocking with 5% BSA in TBST for 2 h, the
membrane was incubated with Ab against STAT4 (BBIAB; Sangon Bio-
tech), VDR (Abcam), LC3 (Abcam), or GAPDH (BBIAB; Sangon Biotech)
overnight at 4˚C, followed by incubation with the respective secondary
Abs for 1 h. Protein bands were checked using ECL detection solution
(Yeasen). In independent Western blot assays, cells for evaluating each of
the targeted proteins were treated in duplicate or triplicate wells in a six-
well plate in each of the experiments. Samples harvested from each well
were run on separated SDS-PAGE gels, followed by transblotting and
specific immune detection.
ELISA
The amounts of IFN-g, TNF-a, and IL-32 in cell supernatants were de-
tected using human cytokine ELISA kits (C608 for human IFN-g; C609
for human TNF-a; C687 for human IL-32a, purchased from Beijing
GenStar), according to the manufacturer’s instructions.
Statistical analysis
Statistical analysis was performed with GraphPad Prism 6.0. All data are
expressed as mean6 SEM. Differences between groups were first assessed
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by a nonparametric t test or ANOVA; the latter was followed by the
Dunnett test or the Tukey multiple-comparison test, as indicated in the
figure legends. The p values are adjusted for multiple comparisons (family-
wise significance [confidence level of 0.05 and 95% confidence interval]).
Results
IL-12+IL-18 cotreatment of Mycobacterium-infected cells
from monocytic and lung epithelial lineages led to inhibition of
intracellular mycobacterial growth
To address whether IL-12 and/or IL-18 directly affected intra-
cellular mycobacterial infection in monocytes/macrophages and
lung epithelial cells, we used an in vitro human infection model (24,
25). Experiments were initiated in a biosafety level-2 laboratory
using less virulent mycobacteria and then were performed using
virulent M. tuberculosis H37Rv strain for confirmation in a bio-
safety level-3 (BSL3) laboratory. Mycobacteria-infected cells
were treated for 72 h with media, recombinant human IL-12 alone,
recombinant human IL-18 alone, or IL-12+IL-18 and then cells
were lysed to release viable intracellular bacteria for measuring
CFU counts on Middlebrook 7H10 agar plates. Thus, A549 cells,
which usually serve as a model for studying the host response of
human type II alveolar epithelial cells to intracellular pathogens
(26), were infected with M. smegmatis and M. bovis BCG. To
select the optimal combination of cytokines to limit intracellular
bacteria, dose-response experiments were performed; a combina-
tion of 50 ng/ml each cytokine was shown a reduced BCG and
M. tuberculosis burden (Supplemental Fig. 1A, 1B). Although IL-
18RAP mRNA and protein were expressed in infected and unin-
fected A549 cells (Supplemental Fig. 2), cotreatment with IL-12
+IL-18, but not IL-12 or IL-18 alone, significantly reduced the
growth of M. smegmatis in A549 cells (Fig. 1A). Approximately
40% inhibition of intracellular M. smegmatis viability was ob-
served compared with medium control (p , 0.0001, Fig. 1A).
IL-12+IL-18 also inhibited intracellular BCG growth in BCG-
infected A549 cells (Fig. 1B).
We then tested whether cotreatment with IL-12+IL-18 inhibited
the growth of mycobacteria in pulmonary epithelial cells, as well as
in human macrophages. We first used PMA-matured THP-1 cells,
which are often used as a model to study the immune response of
human macrophages (27). Cotreatment of BCG-infected THP-1
macrophage cells with IL-12+IL-18 significantly decreased the
growth of intracellular mycobacteria, with ∼50% inhibition
compared with controls (Fig. 1C). We next examined whether
IL-12+IL-18-triggered growth inhibition could also be detected
in hMDMs. Similarly, IL-12+IL-18 cotreatment significantly re-
duced the growth of intracellular BCG in hMDMs, with a mean
inhibition ∼ 40% compared with control treatment (Fig. 1D).
To validate the specificity of IL-12+IL-18 growth inhibition of
intracellular mycobacteria, we performed blocking experiments
using neutralizing Abs. In the presence of IL-12+IL-18, blockade
of IL-12 or IL-18 signaling by neutralizing anti–IL-12 or anti–IL-
18 Ab significantly reduced the intracellular growth of M. smeg-
matis and BCG in hMDMs compared with isotype controls
(Fig. 1E). This was consistent with the finding that IL-12+IL-18
treatment upregulated IL-12A, IL-12B, and IL-18 in BCG-infected
hMDMs (Supplemental Fig. 1C). However, in the absence of
exogenous IL-12+IL-18, neutralization of endogenous IL-12 and
IL-18 in BCG-infected hMDM cultures did not affect intracellular
mycobacteria growth (Supplemental Fig. 1D). Although anti–IL-
12– or anti–IL-18–neutralizing Ab was unable to efficiently pen-
etrate the cell membrane to block endogenous IL-12/IL-18, we
cannot exclude the possibility that concentrations of endogenous
IL-12 and IL-18 induced by mycobacterial infection were not high
enough to inhibit extremely high levels of mycobacterial infection
in cultures. Similar blocking effects by neutralizing anti–IL-12 or
anti–IL-18 Ab were observed in the other three systems involving IL-
12+IL-18 cotreatment of M. smegmatis or BCG in A549 epithelial
cells and THP-1 monocytic cells (Supplemental Fig. 1E–G).
We also sought to examine whether the IL-12+IL-18–mediated
intracellular inhibition of mycobacteria could also be detected at
day 6 after the coculture. As seen in Fig. 1F, IL-12+IL-18
cotreatment significantly restricted intracellular BCG growth in
A549 cells at day 3, as well as at day 6. Taken together, these data
suggest that the simultaneous activation of IL-12 and IL-18 sig-
naling pathways results in potent growth inhibition of intracellular
mycobacteria in human monocytic and lung epithelial lineages.
Cotreatment of hMDMs with IL-12+IL-18 consistently
inhibited intracellular growth of virulent M. tuberculosis
H37Rv
We then sought to determine whether cotreatment of monocytes/
macrophages with IL-12+IL-18 could also inhibit the intracellu-
lar growth of virulentM. tuberculosis bacilli as we demonstrated in
the setting of M. smegmatis and BCG infection. To address this,
we performed growth-inhibition experiments using the virulent
M. tuberculosis H37Rv strain for infection of hMDMs under
BSL3 conditions. Similarly, M. tuberculosis H37Rv–infected
hMDMs were cultured with media or IL-12+IL-18 for 3 d, and CFU
were counted on 7H11 agar plates. Consistent with the findings for
M. smegmatis and BCG, treatment of M. tuberculosis–infected
hMDMs with IL-12+IL-18 also led to significant and reproducible
inhibition of intracellular H37Rv bacilli growth at day 3 (Fig. 2A,
inhibition rate 39%, p = 0.0296). Moreover, IL-12+IL-18 treatment
still showed a suppressive effect at day 6 (Fig. 2B). These results
provided further support that IL-12+IL-18 could restrict the intra-
cellular growth of mycobacteria, including virulent M. tuberculosis.
VDR activation of antimicrobial peptides appeared to be
required for the IL-12+IL-18 cosignaling–mediated growth
inhibition of intracellular mycobacteria
We then conducted studies to explore the mechanism(s) by which
cotreatment of infected cells with IL-12+IL-18 restricts intracel-
lular mycobacterial growth. Because cotreatment with IL-12+IL-
18 similarly inhibited M. tuberculosis and BCG growth in host
cells, we used BCG infection for the in-depth mechanistic ma-
nipulations in a biosafety level-2 laboratory, rather than those
involving M. tuberculosis in complicated BSL3 conditions. We
sought to determine which anti-Mycobacterium effector functions
were activated by IL-12+IL-18 during infection of target cells.
Because mycobacteria can activate the expression of antimicrobial
defense peptides in lung epithelial cells and human macrophages
(28–30), we rationalized that treatment with IL-12+IL-18 would
enhance the expression of these peptides, resulting in growth
inhibition of intracellular mycobacteria. To address this,
BCG-infected cells were treated with IL-12+IL-18 together or
individually or with media control, and RT-qPCR (see primers
information in Table I) was used to assess the expression of VDR
downstream genes CAMP and DEFB4A, encoding cathelicidin
and b-defensin 2, respectively, antimicrobial peptides that are
capable of killing intracellular mycobacteria (30, 31). These ex-
periments revealed that cotreatment with IL-12+IL-18 signifi-
cantly increased the expression of CAMP by up to ∼7-fold after
BCG infection of A549 cells, THP-1 cells, and hMDMs (Fig. 3A).
Similarly, IL-12+IL-18 cosignaling also increased DEFB4A ex-
pression by up to ∼8-fold (Fig. 3B). IL-12+IL-18 treatment still
led to enhanced expression of CAMP and DEFB4A in H37Rv-
infected hMDMs (Fig. 2C). This result is confirmed by the enhanced
expression of protein levels of CAMP in IL-12+IL-18–treated
The Journal of Immunology 2407
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BCG-infected A549 and THP-1 cells, as measured by Western
blot (Fig. 3C). Furthermore, when the expression of CAMP was
impaired (Fig. 3D, 3E), IL-12+IL-18 treatment failed to control
the growth of intracellular BCG compared with media (Fig. 3F,
3G). These results suggest that IL-12+IL-18 cosignaling led to
enhanced expression of genes encoding antimycobacterial peptide,
such as CAMP and DEFB4A, during BCG infection of monocytic
and lung epithelial cell lineages, which contributed to the IL-12
+IL-18–mediated inhibitory effect on intracellular mycobacteria
growth.
Because VDR signaling is required for the induction of CAMP
and DEFB4A, and it mediates the control of intracellular patho-
gens (32, 33), we hypothesized that VDR activation of cathelicidin
and b-defensin 2 might be required for the IL-12+IL-18–induced
growth restriction of intracellular mycobacteria. Initially, we
found that IL-12+IL-18 cosignaling significantly increased the
expression of VDR by 6.4 6 0.6–fold and 4.9 6 0.87–fold during
BCG infection of A549 cells and hMDMs, respectively, but not
THP-1 cells (Fig. 4A). To prove that VDR activation of anti-
mycobacterial peptides was required for the IL-12+IL-18 trig-
gering of the antimycobacterial response, we developed stably
transduced A549 and THP-1 cell lines displaying VDR knock-
down (Fig. 4B, 4E). Notably, knockdown of VDR in BCG-
infected shVDR-transduced A549 cells diminished the ability of
cotreatment with IL-12+IL-18 to upregulate CAMP and DEFB4A
genes compared with control shControl-transduced A549 cells
(Fig. 4C). CAMP protein expression was also reduced by shRNA
knockdown of VDR in BCG-infected A549 and THP-1 cells
treated with IL-12+IL-18 (Fig. 4G). More importantly, shRNA
knockdown of VDR in BCG-infected A549 and THP-1 cells
FIGURE 1. IL-12+IL-18 cotreatment ofMycobacterium-infected cells from monocytic and lung epithelial lineages led to reproducible inhibition of intracellular
mycobacterial growth. (A and B) Survival index reflects the IL-12+IL-18–induced inhibition of intracellular growth ofM. smegmatis orM. bovis BCG in A549 cells.
A549 cells were infected with M. smegmatis or BCG and then cultured for 3 d with 50 ng/ml recombinant human IL-12, recombinant human IL-18, their
combination, or culture media alone. (C) Mean survival index for BCG in THP-1 cells cultured with different treatments. THP-1 cells were first treated with
50 ng/ml PMA for differentiation. Then, differentiated THP-1 cells were infected with BCG and cultured for 3 d with 50 ng/ml recombinant human IL-12,
recombinant human IL-18, their combination, or culture media alone. (D and E) Mean survival index for BCG in hMDMs treated as above. Adherent monocytes
enriched from PBMCs were allowed to differentiate into human primary macrophages under stimulation (50 ng/ml M-CSF) in culture. hMDMs were infected with
BCG and then cultured for 3 d with 50 ng/ml recombinant human IL-12, recombinant human IL-18, their combination, or culture media alone, in the absence or
presence of Ab to IL-12 or IL-18 and isotype controls. (F) IL-12+IL-18 cosignaling decreased the number of intracellular BCG in A549 cells at days 3 and 6. A549
cells were infected with BCG and then cultured for 3–6 d with 50 ng/ml recombinant human IL-12, recombinant human IL-18, or their combination. Data in (A)–(C)
are pooled from five independent experiments; data in (D) and (E) are pooled from four independent experiments using cells from 20 healthy donors; data in (F) are
pooled from eight replicates in two independent experiments. ****p , 0.0001 versus media, ANOVA, followed by the Dunnett test (A–D); ANOVA, followed by
the Tukey multiple-comparison test (E); versus media, repeated ANOVA, followed by the Dunnett test (F).
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abrogated the ability of IL-12+IL-18 cotreatment to restrict the
growth of intracellular mycobacteria (Fig. 4D, 4F). Taken to-
gether, these data suggest that VDR activation is required for the
IL-12+IL-18–induced restriction of intracellular mycobacterial
growth in macrophages and lung epithelial cells.
The p38–MAPK and STAT4 pathways are involved in IL-12+IL-18
cosignaling that led to inhibition of intracellular mycobacteria
Next, studies of T cells and NK cells showed that IL-18 could
activate NF-kB and MAPK–associated PI3K, MEK, and p38
signaling pathways (34, 35). Therefore, we investigated which of
these pathways in monocytes was required for the IL-12+IL-18
cosignaling that induced the growth inhibition of intracellular
mycobacteria. Thus, BCG-infected A549 and hMDM cells were
incubated with individual well-documented inhibitors of the
MAPK and NF-kB pathways in the presence of IL-12+IL-18.
Notably, inhibitors of the NF-kB pathway (PDTC) and the
MEK-MAPK pathway (U0126-EtOH) did not appear to alter the
IL-12+IL-18–induced restriction of intracellular BCG growth
(Fig. 5A, 5B). In contrast, the p38–MAPK inhibitor (SB203580)
significantly blocked the IL-12+IL-18 cosignaling–induced
growth restriction of mycobacteria in BCG-infected hMDMs and
A549 cells (Fig. 5A, 5B). Consistently, we found that IL-12+IL-18
cosignaling could modulate the expression of IL-18Rs in hMDMs,
as seen in T cells and NK cells (15, 34, 35), because cotreatment
with IL-12+IL-18 significantly increased the expression of IL-
18R1 and IL-18RAP, by 5.7 6 2.1 and 5.2 6 2.6–fold, respec-
tively, in mycobacteria-infected hMDMs (Fig. 5C). Furthermore,
treatment with the p38–MAPK inhibitor (SB203580) significantly
inhibited IL-12+IL-18 cosignaling–induced CAMP at the mRNA
and protein levels in BCG-infected hMDMs and THP-1 cells
(Fig. 5D, 5E). These results suggest that the combined action of
IL-12+IL-18 that resulted in the growth inhibition of intracellular
mycobacteria mainly occurred via the p38–MAPK signaling axis
and not via the NF-kB or MEK–MAPK pathway.
Because studies of T cells and NK cells identified STAT4 as a
major downstream molecule for IL-12 signaling (36), we presumed
that the IL-12/STAT4 pathway in monocytic/lung epithelial line-
ages might contribute to IL-12+IL-18 treatment resulting in the
growth inhibition of intracellular mycobacteria. To test this, we
produced lentivirus shRNA-knockdown constructs and developed
stable A549 and THP-1 cell lines displaying STAT4 knockdown,
with shControl serving as control. STAT4 knockdown was con-
firmed in these transduced A549 and THP-1 cells (Fig. 5F, 5H).
Clearly, knocking down STAT4 expression in A549 and THP-1
cells reversed the IL-12+IL-18–induced growth inhibition of
intracellular mycobacteria (Fig. 5G, 5I). Notably, the reversing
effect by the STAT4 knockdown correlated with the reduced
FIGURE 2. IL-12+IL-18 cotreatment in hMDMs consistently inhibited intracellular growth of virulent M. tuberculosis H37Rv. (A) Mean survival index
for intracellular growth inhibition of M. tuberculosis H37Rv strain in hMDMs. M. tuberculosis–infected hMDMs were treated with IL-12+IL-18 or media
for 3 d. Viable bacteria recovered from infected cells were quantified by counting CFU. Data are pooled from two independent experiments using cells from
eight healthy uninfected donors. *p, 0.05, nonparametric t test. (B) IL-12+IL-18 cosignaling decreased the number of intracellularM. tuberculosis H37Rv
bacilli in hMDMs at days 3 and 6. hMDMs were infected with H37Rv and then cultured for 3–6 d in the presence of 50 ng/ml recombinant human
IL-12+IL-18 or media. Data are pooled from two independent experiments from eight uninfected donors. Individual cytokines alone were not found to
inhibit the growth of BCG (Fig. 1) and were not evaluated. Attenuated BCG may be similarly inhibited as M. tuberculosis in IL-12+IL-18–treated hMDMs
(Fig. 1D, 1E). Presumably, at day 6, BCG may be restricted similarly to M. tuberculosis in IL-12+IL-18–stimulated hMDMs. *p , 0.05, nonparametric t
test. (C) Mean fold changes in the expression levels of CAMP, DEFB4A, and IFNG in H37Rv-infected hMDMs in the presence of media or IL-12+IL-18.
Data are from two independent experiments using hMDMs from eight healthy uninfected donors. *p , 0.05, ***p , 0.001, t test.
Table I. Primer sequences for RT-qPCR or RT-PCR used in this study
Gene Symbol Forward (59–39) Reverse (59–39)
DEFB4A ATCAGCCATGAGGGTCTTGT GAGACCACAGGTGCCAATTT
CAMP AGGATTGTGACTTCAAGAAGGACG GTTTATTTCTCAGAGCCCAGAAGC
IL-18R1 GTTGAGTTGAATGACACAGG TCCACTGCAACATGGTTAAG
IL-18Rbeta CTGGACAGAACTCACAGCTC TCAAAGGCTCTAAACCACAG
STAT4 CAGTGAAAGCCATCTCGGAGGA TGTAGTCTCGCAGGATGTCAGC
IFNGR1 CATCACGTCATACCAGCCATTT CATCACGTCATACCAGCCATTT
IFNGR2 CTCCATTCTGCCTGGGTGACAA CGTGGAGGTATCAGCGATGTCA
VDR CTGACCCTGGAGACTTTGAC TTCCTCTGCACTTCCTCATC
EF1A GATTACAGGGACATCTCAGGCTG TATCTCTTCTGGCTGTAGGGTGG
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ability of IL-12+IL-18 to upregulate CAMP protein compared
with the control (Fig. 5J). Taken together, these data suggest that
the p38–MAPK and STAT4 pathways are required for the com-
bined activity of IL-12+IL-18 in the restriction of intracellular
mycobacterial growth in monocytes and pulmonary epithelial
cells.
Autophagy, but not caspase-mediated apoptosis, was involved
in IL-12+IL-18 cosignaling inhibition of intracellular
mycobacteria growth
VDR activation of antimicrobial peptides has been shown to induce
autophagy and mycobactericidal activity (37). Thus, we sought to
examine whether autophagy was involved in the cosignaling in-
duced by IL-12+IL-18 that triggered restriction of intracellular
mycobacterial growth. We assessed an increase in the LC3II/LC3I
ratio or LC3II conversion as a parameter to examine autophagic flux
in BCG-infected target cells treated with IL-12+IL-18 or control.
We found that the IL-12+IL-18 cosignaling in BCG-infected A549
cells led to an increase in the LC3II/LC3I ratio (i.e., autophagy flux)
(Fig. 6A) beyond the background autophagy induced by BCG in-
fection of A549 cells in the absence of cytokines (38, 39). In par-
allel, we developed a stable THP-1 cell line expressing GFP-LC3
using a lentiviral vector to support our results from Western blot
assays. Consistently, IL-12+IL-18 treatment remarkably formed
fluorescent LC3 aggregates/microdots in GFP-LC3–transduced
BCG-infected THP-1 cells (Fig. 6B). Because p38, STAT4, and
VDR were indispensable for the IL-12+IL-18–induced antimi-
crobial response, we sought to determine whether autophagy was
involved in connecting p38/STAT4/VDR activation and growth
inhibition of intracellular mycobacteria. To this end, we examined
whether the conversion of LC3I to LC3II was altered by p38
inhibition, STAT4 knockdown, VDR knockdown, or CAMP
knockdown during IL-12+IL-18 treatment of BCG-infected THP-
1 cells. Treatment with the p38 inhibitor SB203580 reduced IL-12
+IL-18–induced LC3II conversion compared with the control
(DMSO) (Fig. 6C). This was consistent with the decreased for-
mation of LC3II by two well-documented autophagy inhibitors:
wortmannin and 3-MA (40, 41) (Fig. 6C). Moreover, knockdown
of CAMP by shRNA significantly reduced the conversion of LC3I
to LC3II during IL-12+IL-18 treatment of BCG-infected THP-1
cells (Fig. 6D), suggesting a critical role for CAMP in the IL-12
+IL-18 activation of autophagy and BCG growth inhibition in
THP-1 cells. Because we already showed that CAMP was up-
regulated upstream by VDR (Fig. 4G) and STAT4 (Fig. 5J), we
sought to investigate whether shRNA knockdown of VDR or
STAT4 would impact autophagy. As expected, knocking down
VDR or STAT4 reduced the formation of LC3II during the IL-12
+IL-18 treatment of BCG-infected THP-1 cells (Fig. 6E). These
FIGURE 3. CAMP appeared to be required for the IL-12+IL-18–mediated growth inhibition of intracellular mycobacteria. Mean fold changes in the
expression levels of CAMP (A) and DEFB4A (B) in BCG-infected A549 cells, THP-1 cells, and hMDMs in the presence of media, IL-12, IL-18, or IL-
12+IL-18 for 24 h. Data are from four independent experiments using A549 or THP-1 cells and three independent experiments using hMDMs from 12
healthy uninfected donors. *p , 0.05, **p , 0.01, ***p , 0.001, ****p , 0.0001 versus media, ANOVA, followed by the Dunnett test. (C) IL-12+IL-
18 cosignaling led to enhanced expression of CAMP protein levels in BCG-infected A549 cells (left panels) and BCG-infected THP-1 cells (right
panels). Representative Western blots from four replicates (upper panels) and quantitative analysis of CAMP protein levels by densitometry (lower
panels). **p , 0.01, t test. (D and E) Representative Western blots demonstrating shRNA knockdown of CAMP in A549 and THP-1 cells compared
with the shRNA-Control. (F and G) Bar graphs showing that shRNA knockdown of CAMP reverses the growth restriction of intracellular mycobacteria
during IL-12+IL-18 treatment of BCG-infected A549 and THP-1 cells compared with shRNA control. Data are derived from eight replicates in two
independent experiments. ****p , 0.001, t test.
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results suggest that the IL-12+IL-18–mediated activation of
p38/STAT4 can activate VDR-derived CAMP and the autophagy
process.
We then questioned whether the autophagy induced by IL-12
+IL-18 cosignaling contributed to the detectable inhibition of
intracellular mycobacterial growth. To address this, wortmannin
and 3-MA were used for blocking autophagy flux in the context
of IL-12+IL-18–mediated growth restriction of intracellular
mycobacteria. The apoptosis inhibitor zVAD.fmk was evaluated
in parallel, because it inhibits caspase-mediated apoptosis (42).
Notably, the addition of 3-MA or wortmannin to BCG-infected
A549 and THP-1 cultures significantly blocked the IL-12+IL-18
cosignaling restriction of intracellular mycobacterial growth
compared with DMSO control (Fig. 6F). In contrast, the apo-
ptosis inhibitor zVAD.fmk did not have significant blocking
activity in BCG-infected A549 cells and hMDMs (Fig. 6G).
Taken together, these data indicate that the IL-12+IL-18–
mediated activation of p38 and STAT4 activates CAMP and
autophagy and leads to the growth inhibition of intracellular
mycobacteria.
Activation of the IFN-g–IL-32 pathway was required for IL-12
+IL-18 cosignaling–mediated growth inhibition of
intracellular mycobacteria
Finally, we sought to explore the possibility that the combined
action of IL-12+IL-18 activates IFN-g and/or TNF-a, resulting
FIGURE 4. VDR activation of antimicrobial peptides appeared to be required for the IL-12+IL-18–mediated growth inhibition of intracellular myco-
bacteria. (A) Mean fold changes in the expression levels of VDR in BCG-infected A549 cells, THP-1 cells, and hMDMs in the presence of media, IL-12, IL-
18, or IL-12+IL-18. Data are from four independent experiments using A549 or THP-1 cells and from three independent experiments using hMDMs from
12 healthy uninfected donors. ****p , 0.0001 versus media, ANOVA, followed by the Dunnett test. (B) Representative data demonstrating knockdown of
VDR at the mRNA level (left panel, RT-qPCR) and at the protein level (right panel, Western blot) in A549 cells stably transduced with the lentivirus
construct LV-shVDR in comparison with the control. Stably transduced cell lines were selected by puromycin (2 mg/ml) treatment of cultures. (C) Fold
changes in the expression levels of CAMP and DEFB4A in BCG-infected shVDR- and shControl-transduced A549 cells in the presence of media or IL-12
+IL-18 for 24 h. Data were generated by RT-qPCR and pooled from three independent experiments. **p , 0.01, ***p , 0.001, t test. (D) Changes in mean
survival index for BCG in BCG-infected shVDR- and shControl-transduced A549 cells in the presence of media, IL-12, IL-18, or IL-12+IL-18. Data are
derived from four independent experiments. Note that VDR knockdown led to reversion of IL-12+IL-18–mediated inhibition of BCG growth. ****p ,
0.0001 versus media, ANOVA, followed by the Dunnett test. (E) Representative Western blot demonstrating VDR knockdown in THP-1 cells in comparison
with the shRNA control. (F) Bar graph shows that shRNA knockdown of VDR reverses the growth restriction of intracellular mycobacteria during IL-12
+IL-18 treatment of BCG-infected THP-1 cells compared with shRNA control. Data are derived from eight replicates in two independent experiments.
****p , 0.0001, t test. (G) Representative Western blots (from four replicates) show that shRNA knockdown of VDR abrogated the ability of IL-12+IL-18
treatment to induce CAMP expression in BCG-infected A549 and THP-1 cells (upper panel). The bar graphs show quantitative analysis of CAMP protein
levels by densitometry (lower panels). **p , 0.01, ***p , 0.001, t test.
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in the induction of downstream genes that mediate growth in-
hibition of intracellular mycobacteria (32, 41, 43–45). hMDMs,
infected or not with BCG, were treated with media, IL-12,
IL-18, or IL-12+IL-18 for 3 d, and culture supernatants were
assessed for IFN-g and TNF-a. Treatment of hMDMs by IL-12
and/or IL-18 without BCG infection did not significantly in-
duce secretion of IFN-g and TNF-a in culture superna-
tant (data not shown). Similarly, in BCG-infected hMDMs,
IL-18 alone did not induce IFN-g release; however, IL-12 did
so to a moderate degree in BCG-infected macrophages.
Cotreatment of BCG-infected hMDMs with IL-12+IL-18 led
to secretion of significantly higher levels of IFN-g than did
the addition of IL-12 alone (Fig. 7A, 444 6 15 versus 275 6
21 pg/ml), suggesting that additional innate signaling from
mycobacteria was required for induction of IFN-g. In con-
trast, there was no significant change in TNF-a secretion
(Fig. 7B). Consistently, cotreatment with IL-12+IL-18 up-
regulated expression of the IFN-g receptors IFNGR1 and
IFNGR2 on target cells at the mRNA level (Supplemental
Fig. 3C). In addition, IL-12+IL-18, although facilitating
FIGURE 5. p38–MAPK and STAT4 pathways were indispensable to IL-12+IL-18–mediated inhibition of intracellular mycobacteria. Changes in the
mean survival index of BCG in IL-12+IL-18–cotreated A549 cells (A) and hMDMs (B) in the absence and presence of the chemical inhibitors PDTC (10 mM),
U0126 (10 mM), SB203580 (10 mM), and DMSO in the 3-d culture. Data were pooled from three independent experiments using A549 cells (A) and
five experiments using hMDMs derived from 15 healthy uninfected donors (B). ****p , 0.0001, ANOVA, followed by the Tukey multiple-comparisons
test. (C) Mean fold changes in the expression levels of the IL-18R genes IL-18R1 and IL-18RAP in BCG-infected hMDMs incubated for 24 h with media,
IL-12, IL-18, or IL-12+IL-18. Fold changes were calculated using the expression levels of cytokine treatment versus those of media control. Data were
generated using RT-qPCR and pooled from three independent experiments using hMDMs from 12 healthy uninfected donors. *p, 0.05, **p, 0.01 versus
media, ANOVA, followed by the Dunnett test. Inhibition of p38 hindered enhanced expression of CAMP mRNA levels in BCG-infected hMDMs (D) and
CAMP protein levels in BCG-infected THP-1 cells (E) treated by IL-12+IL-18. Data in (D) are derived from three independent assays using nine healthy
uninfected donors. (E) The Western blot is a representative from four replicates (upper panel). The bar graph shows pooled data for OD analysis (lower
panel). *p , 0.05, t test. (F) Representative data demonstrating knockdown of the transcription factor STAT4 in A549 cells stably transduced with the
lentiviral construct LV-shSTAT4 in comparison with the control. (G) Mean survival index for BCG in shSTAT4- and shControl-transduced A549 cells in the
presence of media, IL-12, IL-18, or IL-12+IL-18. Note the reversion of IL-12+IL-18–mediated inhibition in the setting of STAT4 knockdown. Data were
derived from four independent experiments. ****p , 0.0001 versus media, ANOVA, followed by the Dunnett test. (H) Representative Western blot shows
shRNA knockdown of STAT4 in THP-1 cells in comparison with the shRNA control. (I) Bar graph shows that shRNA knockdown of STAT4 reverses the
growth restriction of intracellular mycobacteria during IL-12+IL-18 treatment of BCG-infected THP-1 cells compared with the shRNA control. Data are
derived from eight replicates in two independent experiments. ****p , 0.001, t test. (J) Representative Western blots (from four replicates) shows that
shRNA knockdown of STAT4 reduced CAMP protein expression levels during IL-12+IL-18 treatment of BCG-infected A549 and THP-1 cells (upper
panel). The bar graphs show quantitative analysis of CAMP protein levels by densitometry (lower panels). *p , 0.05, **p , 0.01, t test. ns, not significant.
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IFN-g production, led to the induction of significantly higher
levels of IL-32 than did treatment with IL-18 alone (Fig. 7C),
implicating a possible IL-12+IL-18 → IFN-g → IL-32 acti-
vation axis (32, 43).
To authenticate that IL-12+IL-18 activation of the IFN-g
pathway contributed to inhibition of intracellular mycobacteria,
we blocked IFN-g or TNF-a with neutralizing mAbs. The addi-
tion of neutralizing anti–IFN-g Ab, but not anti–TNF-a Ab, sig-
nificantly abrogated the IL-12+IL-18–mediated growth inhibition
of intracellular mycobacteria in BCG-infected hMDMs (Fig. 7D).
Consistently, blockade of IFN-g also significantly reduced the
IL-12+IL-18–mediated induction of IL-15 and IL-32 (Fig. 7E).
Moreover, neutralization of IFN-g in IL-12+IL-18–treated BCG-
infected hMDMs resulted in reduced expression of CAMP and
decreased autophagy (Fig. 7F, 7G). These data suggested that
activation of the IL-12+IL-18 → IFN-g → IL-15/IL-32 → CAMP
→ autophagy pathway was required for the IL-12+IL-18–induced
growth inhibition of intracellular mycobacteria. Of note, IL-12
+IL-18 activation of the IL-12+IL-18 → IFN-g → IL-15 → IL-32
pathway did not appear to be negated by type I IFN (IFN-b),
which was previously shown to inhibit IFN-g–induced antimi-
crobial capability (46, 47). The addition of IFN-b enhanced
FIGURE 6. Autophagy, but not caspase-mediated apoptosis, was involved in the IL-12+IL-18–induced inhibition of intracellular mycobacteria
growth. (A) Representative Western blots (left panel) displaying autophagy-related proteins LC3II and LC3I in lysates from BCG-infected hMDMs
treated for 6 h with media, IL-12, IL-18, or IL-12+IL-18. Bar graph of the ratio of the intensities of LC3II/LC3I bands from the Western blot (right
panel, n = 3). (B) Representative fluorescence images of individual cells treated with IL-12+IL-18 or media control in the presence or absence of BCG
infection showing that GFP-LC3 punctae or fluorescent GFP-LC3 aggregates of the autophagy machinery were formed after IL-12+IL-18 treatment of
GFP-LC3–transduced BCG-infected THP-1 cells (left panel; original magnification 3400). Bar graph showing comparative quantitation of GFP-LC3
punctae per cell (right panel; n $ 25 cells for each group in three independent experiments). Low background of fluorescence dots is seen in GFP-LC3
THP-1 cells treated with media or IL-12+IL-18. Representative Western blots show that conversion of LC3II (autophagy flux) was reduced by the p38
inhibitor SB203580/autophagy inhibitors 3-MA and wortmannin (C) or shRNA knockdown of CAMP, VDR, and STAT4 (D and E) during IL-12+IL-18
treatment of BCG-infected THP-1 cells from four replicates (upper panels). Quantitative analysis of relative LC3II/LC3I ratios by densitometry (lower
panels). ****p , 0.0001 versus DMSO, ANOVA followed by the Dunnett test (C). *p , 0.05, t test (D); **p , 0.01, ***p , 0.001 versus shControl,
ANOVA, followed by the Dunnett test (E). (F) A 3-d treatment with the autophagy-blocking reagent 3-MA (10 mM) or wortmannin (10 mM) could
abrogate the IL-12+IL-18–mediated inhibition of intracellular BCG in BCG-infected hMDM or A549 cells compared with DMSO control. (G) A 3-d
treatment with the apoptosis-blocking reagent zVAD.fmk (10 mM) was not able to abrogate the IL-12+IL-18–mediated inhibition of intracellular BCG
in BCG-infected hMDMs or A549 cells. In the absence of IL-12+IL-18, the autophagy inhibitors 3-MA and wortmannin, but not zVAD.fmk, have
reversed impact on mycobacterial growth (Supplemental Fig. 3B). Data in (F) and (G) are pooled from four independent experiments using A549 cells
and three independent experiments using hMDMs from 12 healthy uninfected donors. ****p , 0.0001, ANOVA, followed by the Tukey multiple-
comparisons test. ns, not significant.
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intracellular BCG growth in infected hMDMs in the absence of
IL-12+IL-18 treatment but not in IL-12+IL-18–cotreated cells
(Supplemental Fig. 4).
Discussion
Activation of the innate immune response triggers the release of
cytokines that induce inflammation and instruct the adaptive T cell
response. Two key innate cytokines induced by mycobacteria and
involved in host defense are IL-12 (10–13, 16) and IL-18 (14–16,
48, 49). These cytokines act individually on NK and T cells (11,
17, 48, 50, 51); however, together, IL-12 and IL-18 provide a
potent stimulus for innate instruction of the adaptive T cell
response toward Th1 cell differentiation (17). The current study
provides evidence that together, IL-12 and IL-18 trigger anti-
mycobacterial responses against intracellular pathogens in innate
cells, including macrophages and pulmonary epithelial cells, in-
volving the cosignaling of p38–MAPK and STAT4, activation of
VDR-derived CAMP or b-defensin 2, and autophagy. Moreover,
the ability of IL-12+IL-18 to induce the production of IFN-g by
macrophages was required for upregulation of the antimicrobial
activity against M. tuberculosis, identifying a common link be-
tween the innate and adaptive immune responses. Our data pro-
vide new insight into the combined role of IL-12+IL-18 in host
defense, with clinical relevance in the context that polymorphisms
FIGURE 7. Activation of the IFN-g–dependent antimycobacterial pathway was required for the IL-12+IL-18 cosignaling–mediated growth inhibition of
intracellular mycobacteria in human macrophages. Mean cytokine protein concentrations for IFN-g (A), TNF-a (B), and IL-32 (C) in culture supernatants
from BCG-infected hMDMs in the presence of media, IL-12, IL-18, or IL-12+IL-18. Culture conditions were the same as in Fig. 1D. Cytokine proteins
were measured by ELISA. Data were pooled from three independent experiments using hMDMs from 12 healthy uninfected donors. ****p , 0.0001,
ANOVA, followed by the Tukey multiple-comparisons test. (D) IFN-g blockade (left panel) but not TNF-a blockade (right panel) impacts the mean survival
index for BCG in IL-12+IL-18–treated hMDMs. BCG-infected hMDMs were treated with media or IL-12+IL-18 in the presence of neutralizing anti–IFN-g
Ab, anti–TNF-a Ab, and their isotype controls (ISO) (5 mg/ml for each), CFU were counted, and the survival index was calculated. In the absence of IL-12
+IL-18, anti–IFN-g or anti–TNF-a Ab does not lead to changes in intracellular mycobacterial growth (Supplemental Fig. 3A). Data are derived from three
independent experiments using hMDMs from 12 healthy uninfected donors. ****p , 0.0001, ANOVA, followed by the Tukey multiple-comparisons test.
(E) IFN-g blockade–induced abrogation of intracellular BCG growth coincided with decreased expression of IL-15 and IL-32 in BCG-infected hMDMs in
comparison with IL-12+IL-18 without anti–IFN-g or ISO. The expression levels of IL-15 and IL-32 mRNA in BCG-infected hMDMs were quantified by
RT-qPCR. Data are derived from three independent experiments using hMDMs from 12 healthy uninfected donors. ***p , 0.001, **p , 0.01, ANOVA,
followed by the Tukey multiple-comparisons test. (F) Representative Western blot shows that anti–IFN-g–neutralizing Ab, but not ISO, reduced CAMP
expression during IL-12+IL-18 treatment of BCG-infected hMDMs (left panel). Quantitative analysis of CAMP protein levels by densitometry (right
panel). Data are derived from six replicates. **p ,0.01, t test. (G) Representative Western blot shows that anti–IFN-g–neutralizing Ab, but not ISO,
reduced the conversion of LC3II during IL-12+IL-18 treatment of BCG-infected hMDMs (left panel). Quantitative analysis of relative LC3II/LC3I ratios by
densitometry (right panel). Data are derived from six replicates. **p , 0.01, t test. ns, not significant.
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of IL-12 and IL-18 are reported in patients with tuberculosis (TB)
(52, 53).
The ability of macrophages to upregulate antimicrobial peptide
expression provides one mechanism of innate host defense against
intracellular pathogens (30). BCG infection also triggers the ac-
tivation of microbicidal peptides in the A549 epithelial cell line
through multiple mechanisms (28, 29). Our data suggest that IL-
12+IL-18 treatment induces the upregulation of the antimicrobial
peptide genes CAMP and DEFB4A. Particularly, the increased
patterns of CAMP and autophagy were observed in lung epithelial
cells and human macrophages, suggesting a common mechanism
of the IL-12+IL-18–induced antimicrobial response in these two
different cell types. Consistent with multiple studies, the increased
expression of antimicrobial peptide genes might represent the
downstream effector function of the IL-12+IL-18–induced growth
inhibition of intracellular mycobacteria (33, 54, 55). Consistent
with the demonstration that both of these antimicrobial peptide
genes are regulated by a transcription factor, VDR (31, 37, 55), we
found that blockade of VDR signaling by transduction with
shRNA lentivirus affected IL-12+IL-18–induced microbicidal
activity. Furthermore, the requirement of VDR explains, in part,
the vital role of autophagy in the clearance of intracellular bacteria
induced by the combined action of IL-12+IL-18 (56).
IL-12 and IL-18 cooperate to activate cosignaling pathways and
inhibit the intracellular growth of mycobacteria in target host cells,
because the antimycobacterial effect cannot be induced by either
alone or in the presence of anti–IL-12– or anti–IL-18–neutralizing
Ab in the cotreatment culture. Together, IL-12+IL-18 leads to
signaling via the p38–MAPK and STAT4 pathways, which are
required to inhibit the growth of intracellular mycobacteria, be-
cause small molecule inhibition of p38–MAPK or knockdown of
STAT4 clearly reduced the antimicrobial effect. Although block-
ing the p38–MAPK pathway strongly reduced the IL-12+IL-18–
induced antimycobacterial activity, blocking the MEK–MAPK
and NF-kB pathways had no effect. The discrepant requirement of
specific MAPK pathways provides new insights into how the host
intracellular pathway–network regulates intracellular pathogen
survival (37).
The IL-12+IL-18–induced growth restriction of intracellular
bacteria is dependent on VDR-derived CAMP and autophagy.
IL-12+IL-18 upregulation of VDR mRNA in THP-1 cells is not
as striking as that in A549 cells or hMDMs, presumably due to
complex cell-type factors. However, knockdown of VDR protein
by shRNA manipulation consistently abrogates the IL-12+IL-
18–induced activation of antimicrobial peptides and reversed the
IL-12+IL-18–mediated inhibition of BCG growth in THP-1 and
A549 cells. These results suggest that VDR is required for the
IL-12+IL-18–induced activation of a downstream antimicrobial
pathway in both cell types. Autophagy has been shown to fa-
cilitate the delivery of antimicrobial peptides to the intracellular
compartments containing the pathogen (57). The data in our
study, using chemical inhibitors, emphasize the significant role
of autophagy, which is consistent with multiple reports (32, 39,
58–60). Although caspase-mediated apoptosis has been associ-
ated with the suppression of intracellular bacterial growth (37,
61, 62), it has been suggested by other investigators that apo-
ptosis may facilitate the spread of mycobacteria during infection
in vivo in zebrafish and in a mouse model (63, 64). Our data
suggest that IL-12+IL-18–induced antimycobacterial activity
does not require the induction of apoptosis in BCG-infected
hMDMs and A549 cells, indicating that autophagy, but not ap-
optosis, contributes to lower bacillary load. Also, these data
partially explain the unnecessary role of endogenous TNF-a,
which is known to induce apoptosis (37).
It is well known that the production of IFN-g by the adaptive
T cell response is necessary for immune protection against TB
(65–67). In addition, it has been shown that IFN-g is produced by
cells of the innate immune system, including NK cells (18) and
murine macrophages (20, 21), in response to IL-12+IL-18, as well
as in response to mycobacterial infection in human macrophages
(19). A surprising finding of the current study was that the ability
of IL-12+IL-18 to induce, in macrophages, the autonomous pro-
duction of IFN-g, a cytokine typically associated with the adaptive
T cell response, was required for generation of an innate antimi-
crobial response. We found that treatment of macrophages with
IL-12 and IL-18 induced IL-15 and IL-32, which prompted the
activation of the VDR leading to upregulation of antimicrobial
peptides known to inhibit the growth of intracellular mycobac-
teria, the identical pathway induced by exogenous treatment with
IFN-g (32). Evidence for this vital role of IFN-g was demon-
strated by experiments in which neutralizing IFN-g blockade ab-
rogated the IL-12+IL-18–induced production of IL-15 and IL-32,
as well as the antimycobacterial response. These data provide new
insight into the mechanism of innate antimicrobial activity against
M. tuberculosis in human macrophages, delineated as IL-12+IL-
18 → IFN-g → IL-15/IL-32 → antimicrobial peptides and auto-
phagy. Furthermore, innate and adaptive immune responses have
evolved to have distinct functions, yet both have retained the
ability to produce IFN-g to activate the vitamin D–dependent
antimicrobial pathway (32). It is noteworthy that IL-12+IL-18
activation of IFN-g was not inhibited by IFN-b. This finding
suggests that the combined action of IL-12+IL-18 can override the
immunosuppressive action of type I IFNs, which are upregulated
as part of the pathogenesis of TB and have been shown to nega-
tively regulate the host immune defense against bacterial infection
(37, 47, 68). One mechanism by which type I IFNs downregu-
late IFN-g–induced immune responses is via the production of
IL-10 (47).
IL-12+IL-18–induced restriction of mycobacteria in pulmonary
epithelial cells does not involve the production of IFN-g or IL-15,
as seen in the setting of mycobacteria-infected macrophages.
However, the restriction of intracellular mycobacterial growth in
lung epithelial cells requires VDR-derived antimicrobial peptides
and autophagy, suggesting the existence of an alternate pathway
for the induction of these host defense responses. Importantly, IL-
12+IL-18–mediated activation of p38/STAT4 can activate VDR,
VDR-derived CAMP, and autophagy, leading to inhibition of in-
tracellular mycobacterial growth in macrophage and pulmonary
epithelial cell lineages.
IL-12+IL-18 cosignaling does not seem to upregulate TNF-a
production, and neutralizing anti–TNF-a Ab blockade fails to
reduce or abrogate the IL-12+IL-18–mediated growth inhibition
of intracellular mycobacteria. Several points might help to explain
the lack of a role for TNF-a in the IL-12+IL-18 restriction of
intracellular mycobacteria. First, an absence of changes in low
TNF-a baseline after IL-12+IL-18 treatment suggests that low-
level TNF-a does not contribute to the intrinsic function of the
IL-12+IL-18–induced growth inhibition of mycobacteria. We
found that concentrations of exogenous TNF-a $ 50 ng/ml me-
diated the inhibition of intracellular mycobacteria (data not
shown). Second, in vitro blockade of the TNF-a signal might not
be sufficient to uncover upregulation of intracellular mycobacteria
growth. In fact, intracellular mycobacterial growth could not be
enhanced by three well-documented TNF-a–blockade drugs ca-
pable of reactivating latent TB (69). Third, in vitro TNF-a–
mediated growth inhibition of intracellular mycobacteria appears
to require granzyme A or other factors produced by T cells, and
such cooperative TNF-a inhibition is independent of autophagy
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(41). In contrast, IL-12+IL-18–induced inhibition involves VDR
induction of cathelicidin, b-defensin 2, and autophagy, without the
need for granzyme A.
Whether the IL-12+IL-18–induced antimicrobial pathway is
active in vivo appears to be complex and beyond the scope of the
current study. Natural M. tuberculosis infection of humans cer-
tainly induces the production of IL-12/IL-18 (11, 15), and it will
be interesting to determine whether IL-12/IL-18 rapidly produced
upon M. tuberculosis exposure can help to control infection or
even sterilizing immunity. In this natural setting, a much lower
concentration of IL-12+IL-18 may be sufficient for M. tuberculosis
growth restriction.
Thus, treatment of macrophages and lung epithelial cells with
IL-12+IL-18 induced an antimicrobial response, providing ev-
idence for a mechanism involving the p38–MAPK and STAT4
signaling pathways, the production of the antimicrobial peptide
cathelicidin, as well as enhanced induction of autophagy. Fur-
thermore, IL-12+IL-18 treatment led to the production of IFN-g
and the induction of IL-32 and IL-15 in human macrophages.
Defining this novel mechanism may also provide innovative
treatment strategies for blocking further transmission of
M. tuberculosis and reactivation of TB in the already-infected
population.
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